Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

• DOI: 10.1200/jco.21.02286
• Publication Date: 2021-11-18T21:21:48Z
• Authors: Christopher J. Gi...; Haesook T. Kim; Lin Zhao; H. Moses Murdock; Bryan Hambley; Alana Ogata; Rafael Madero-Mar...; Shiyu Wang; Lisa Green; Mark Fleharty; Tyler Dougan; Chi-An Cheng; Brendan Blumenstiel; Carrie Cibulskis; Junko Tsuji; Madeleine Duran; Christopher D. Gocke; Joseph H. Antin; Sarah Nikiforow; Amy E. DeZern; Yi-Bin Chen; Vincent T. Ho; Richard J. Jones; Niall J. Lennon; David R. Walt; Jerome Ritz; Robert J. Soiffer; Lukasz P. Gondek; R. Coleman Lindsley
• Keywords: Adult; 0301 basic medicine; Leukemia; Adolescent; Calcineurin Inhibitors; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease; Infant; ORIGINAL REPORTS; DNA Methyltransferase 3A; Dioxygenases; 3. Good health; DNA-Binding Proteins; 03 medical and health sciences; Child, Preschool; Hematologic Neoplasms; Chronic Disease; Cytokines; Humans; Female; Clonal Hematopoiesis; Child; Alleles; Aged

Clonal hematopoiesis (CH) can be transmitted from a donor to recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on outcomes and graft alloimmune function uncertain.